These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
407 related articles for article (PubMed ID: 22673746)
1. Recent advances on NOTCH signaling in T-ALL. Tzoneva G; Ferrando AA Curr Top Microbiol Immunol; 2012; 360():163-82. PubMed ID: 22673746 [TBL] [Abstract][Full Text] [Related]
2. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia. Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525 [TBL] [Abstract][Full Text] [Related]
3. The role of NOTCH1 signaling in T-ALL. Ferrando AA Hematology Am Soc Hematol Educ Program; 2009; ():353-61. PubMed ID: 20008221 [TBL] [Abstract][Full Text] [Related]
4. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Hales EC; Taub JW; Matherly LH Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552 [TBL] [Abstract][Full Text] [Related]
6. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia. Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of Notch inhibition in T-cell acute lymphoblastic leukemia: rationale, caveats and promises. Sarmento LM; Barata JT Expert Rev Anticancer Ther; 2011 Sep; 11(9):1403-15. PubMed ID: 21929314 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia. Palomero T; Ferrando A Clin Lymphoma Myeloma; 2009; 9 Suppl 3(Suppl 3):S205-10. PubMed ID: 19778842 [TBL] [Abstract][Full Text] [Related]
9. Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors. Silva A; Jotta PY; Silveira AB; Ribeiro D; Brandalise SR; Yunes JA; Barata JT Haematologica; 2010 Apr; 95(4):674-8. PubMed ID: 20015880 [TBL] [Abstract][Full Text] [Related]
10. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Real PJ; Tosello V; Palomero T; Castillo M; Hernando E; de Stanchina E; Sulis ML; Barnes K; Sawai C; Homminga I; Meijerink J; Aifantis I; Basso G; Cordon-Cardo C; Ai W; Ferrando A Nat Med; 2009 Jan; 15(1):50-8. PubMed ID: 19098907 [TBL] [Abstract][Full Text] [Related]
11. Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. Mirandola L; Chiriva-Internati M; Montagna D; Locatelli F; Zecca M; Ranzani M; Basile A; Locati M; Cobos E; Kast WM; Asselta R; Paraboschi EM; Comi P; Chiaramonte R J Pathol; 2012 Apr; 226(5):713-22. PubMed ID: 21984373 [TBL] [Abstract][Full Text] [Related]
12. Notch in T-ALL: new players in a complex disease. Koch U; Radtke F Trends Immunol; 2011 Sep; 32(9):434-42. PubMed ID: 21775206 [TBL] [Abstract][Full Text] [Related]
13. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Paganin M; Ferrando A Blood Rev; 2011 Mar; 25(2):83-90. PubMed ID: 20965628 [TBL] [Abstract][Full Text] [Related]
14. Synergistic antileukemic therapies in Sanchez-Martin M; Ambesi-Impiombato A; Qin Y; Herranz D; Bansal M; Girardi T; Paietta E; Tallman MS; Rowe JM; De Keersmaecker K; Califano A; Ferrando AA Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2006-2011. PubMed ID: 28174276 [TBL] [Abstract][Full Text] [Related]
15. CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors. Palomero T; Barnes KC; Real PJ; Glade Bender JL; Sulis ML; Murty VV; Colovai AI; Balbin M; Ferrando AA Leukemia; 2006 Jul; 20(7):1279-87. PubMed ID: 16688224 [TBL] [Abstract][Full Text] [Related]
16. More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment. López-Nieva P; González-Sánchez L; Cobos-Fernández MÁ; Córdoba R; Santos J; Fernández-Piqueras J Oncologist; 2021 Feb; 26(2):e298-e305. PubMed ID: 33191568 [TBL] [Abstract][Full Text] [Related]
17. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia. De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257 [TBL] [Abstract][Full Text] [Related]
18. The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia. Sanchez-Martin M; Ferrando A Blood; 2017 Mar; 129(9):1124-1133. PubMed ID: 28115368 [TBL] [Abstract][Full Text] [Related]
19. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. Aste-Amézaga M; Zhang N; Lineberger JE; Arnold BA; Toner TJ; Gu M; Huang L; Vitelli S; Vo KT; Haytko P; Zhao JZ; Baleydier F; L'Heureux S; Wang H; Gordon WR; Thoryk E; Andrawes MB; Tiyanont K; Stegmaier K; Roti G; Ross KN; Franlin LL; Wang H; Wang F; Chastain M; Bett AJ; Audoly LP; Aster JC; Blacklow SC; Huber HE PLoS One; 2010 Feb; 5(2):e9094. PubMed ID: 20161710 [TBL] [Abstract][Full Text] [Related]